There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 1 | 4 | 8896.5 |
| 5 | 14 | 8895.5 |
| 3 | 130 | 8895 |
| 1 | 4 | 8894.5 |
| 1 | 29 | 8894 |
| Ask | Qty | Orders |
|---|---|---|
| 8899.5 | 3 | 7 |
| 8900 | 9 | 91 |
| 8900.5 | 8 | 35 |
| 8901 | 4 | 14 |
| 8901.5 | 4 | 31 |
Annual Revenue,rose 15.58%, in the last year to ₹25,420.1 Cr. Its sector's average revenue growth for the last fiscal year was 19.48%.Annual Net Profit,rose 34.29% in the last year to ₹1,941.7 Cr. Its sector's average net profit growth for the last fiscal year was -20.74%.Return on Equity(ROE),for the last financial year was 20.48%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.
Founded in 1983 to make world‑class healthcare accessible in India, Apollo Hospitals Enterprise Limited (AHEL) has grown into an integrated healthcare ecosystem spanning hospitals, retail health and diagnostics, digital health and large‑scale pharmacy distribution. The network includes 73 hospitals, 10,100+ beds, 13,000+ doctors, 2,900+ retail health centres and 6,600+ pharmacies; in FY 2025 Apollo served 7.38 million outpatients with an average length of stay of 3.3 days and 6,04,240 discharges. Its digital platform Apollo 24/7 provides virtual consultations, e‑pharmacy and remote care, complementing AI‑driven diagnostics and robotic‑assisted procedures across the system.
Apollo operates mainly in India, supported by international entities including Apollo Singapore Pte Ltd and Apollo Hospitals (UK) Ltd, which sit within the broader group structure. Key brands across the portfolio include Apollo 24/7 (digital health), Apollo Pharmacy, and retail health formats covering clinics, diagnostics, Spectra, Cradle, Sugar, Dental and Dialysis, integrated to improve continuity of care and outcomes.
Apollo Hospitals Enterprise Limited’s Business Segments and Revenue Breakdown
Apollo reports three operating and reportable segments, plus Others.
Breakdown of Apollo Hospitals’ segment revenue for FY2025:
The Board approved a Composite Scheme of Arrangement (June 30, 2025) to demerge the omni‑channel pharmacy distribution and digital health platform (including Remote Telehealth) and the investment in Apollo HealthCo Limited, and to merge Keimed Private Limited, Apollo HealthCo’s omni‑channel pharmacy distribution and Apollo 24×7 digital platforms into a 100% subsidiary, Apollo HealthTech Limited (NewCo).
Shareholders of Apollo Hospitals Enterprise Limited (AHEL) would receive 195.2 NewCo shares for every 100 AHEL shares, with NewCo listing targeted in 18–21 months, subject to approvals and NCLT process around February 2026 .
During FY 2025, Apollo HealthCo Limited invested 7,250 million in Keimed Private Limited, strengthening the distribution platform pending completion of the proposed structure.
Capacity expansion remains a priority: the company highlights 10,100+ beds in FY 2025, with plans for 11,750+ by FY 2027 and 13,750+ beds approved through FY2030, and a network of 800+ telemedicine centres extending reach beyond metros. In retail pharmacy, the platform added 607 outlets in FY 2025 (net increase 596), continuing its footprint expansion across states through an omnichannel model that supports patient retention and private‑label cross‑sell.
For Q4 FY26, Apollo Hospitals Enterprise Ltd reported: Revenue (Net Sales): ₹24385.00 Cr - Up 3.16% year-on-year from ₹23637.00 Cr in Q3 FY26. Net Income (PAT): ₹3824.00 Cr - Down -0.29% year-on-year from ₹3835.00 Cr in Q3 FY26.
Over the last 6 months, Apollo Hospitals Enterprise Ltd has given a return of 21.63%. The stock was priced at ₹7,268.50 on 12 Jan 2026 and has Rise to ₹8,841.00 as of 11 Jul 2026, a change of ₹1,572.50 per share.
The intraday low for Apollo Hospitals Enterprise Ltd on the NSE today was ₹8,756.50. The stock's 52-week low stands at ₹6,696.50, recorded on 23 Jan 2026. Today's low is 30.76% above the 52-week low, indicating the stock is trading well above its yearly lows.
The all-time high (ATH) for Apollo Hospitals Enterprise Ltd was ₹8,893.50, recorded on 03 Jul 2026. At the current price of ₹8,841.00, the stock is trading 0.59% below its all-time high. The all-time low recorded was ₹322.60 on 27 Jan 2010.
Yes,Apollo Hospitals Enterprise Ltd has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 81.75 per share between FY2022 and FY2026, with the most recent dividend of ₹10.00 per share for May 26. At the current market price of ₹8,841.00, the trailing dividend yield of Apollo Hospitals Enterprise Ltd stands at 20.00%.
Apollo Hospitals Enterprise Ltd has delivered a return of 17.62% over the last 3 months. The stock was trading at ₹7,511.50 on 10 Apr 2026 and is currently at ₹8,841.00 as of 11 Jul 2026, reflecting a Gain of ₹1,329.50 per share over this period.
The intraday high for Apollo Hospitals Enterprise Ltd on the NSE today (11 Jul 2026) was ₹8,920.50. This compares to the 52-week high of ₹8,950.00 recorded on 07 Jul 2026. Today's high was -0.33% below the 52-week high.
As of 11 Jul 2026, the share price of Apollo Hospitals Enterprise Ltd is ₹8,841.00 on the NSE and ₹8,843.70 on the BSE. The stock opened at ₹8,849.00, touched a high of ₹8,920.50 and a low of ₹8,756.50 during today's session.
Apollo Hospitals Enterprise Ltd has delivered a 135.92% absolute return over the past 5 years, equivalent to a CAGR of 18.73% per annum. The stock was priced at ₹3,747.46 in Jul 2021 and has risen to ₹8,841.00 as of 11 Jul 2026. An investment of ₹1,00,000 in Apollo Hospitals Enterprise Ltd five years ago would be worth ₹2,35,920.00 today.
Apollo Hospitals Enterprise Ltd has delivered 22.97% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹8,950.00 on 07 Jul 2026 and a 52-week low of ₹6,696.50 on 23 Jan 2026. It is currently trading at ₹8,841.00 as of 11 Jul 2026.
